Most lenders won't touch cannabis or CBD. We fund compliant UK operators with the capital they need to grow — legally and confidently.



2,400+ businesses fundedNo upfront fees • Free quote in minutesTwo banks told me to come back next year. These guys had the money in my account by Thursday.
Nobody ran a hard search, nobody played games. The offer they showed me is the offer I got.
Bought a second van right before our busy season. It paid for itself in two months.


We fund the business on its revenue — not your possessions.

Repayment follows your actual sales — strong months pay more, slow months ease up.

Most owners see offers the same day and money within ~24 hours of signing.
The cannabis and CBD industry has a banking problem. Despite CBD being a legal consumer product in the UK and medical cannabis being prescribable since 2018, most banks and traditional lenders refuse to work with cannabis-adjacent businesses. This leaves compliant, licensed operators — many turning over millions a year — without access to the basic financial tools every other industry takes for granted: lines of credit, equipment financing and growth capital.
Granton Hale Capital is one of the few funding sources that actively serves the legal cannabis and CBD industry. We work with FSA-compliant CBD product manufacturers, hemp growers operating under Home Office licence, licensed medical-cannabis operators, and retailers whose products sit on the FSA Novel Foods public list. We don't treat the sector as a reputational risk — we treat it as a high-growth industry with unique funding needs, and a soft search means exploring your options never affects your credit score.
Our cannabis and CBD clients use funding for cultivation equipment (lighting, HVAC, irrigation), extraction and processing kit, retail and lab build-outs, inventory purchasing, compliance and security infrastructure, and working capital to manage a sector where mainstream payment processing is often unavailable or expensive.
Most high-street banks and payment processors (Stripe, PayPal and the like) refuse to serve cannabis and CBD businesses, forcing operators onto expensive specialist providers, restricted card processing, and cash-heavy operations that drive up security costs and complexity.
Home Office cultivation licences, GMP-standard facilities for medical product, and FSA Novel Foods authorisation dossiers can run to £100K–£400K+, while facility build-outs (grow rooms, extraction labs, retail) require £150K–£1.5M+ before generating a single pound of revenue.
Home Office security conditions, lab testing for cannabinoid content, traceability, CCTV, alarm and vault storage create ongoing expenses of £40K–£150K+ a year that other industries simply don't face.
The FSA Novel Foods backlog, the strict controlled-cannabinoid limit on consumer CBD, and an evolving legal framework create uncertainty that mainstream lenders use as a reason to decline — even for fully compliant, profitable operators.
Fund inventory purchases, cover operational expenses, and manage the cash-flow demands of a cash-intensive sector with limited banking access.
Finance cultivation equipment (LED lighting, HVAC, irrigation), extraction systems, packaging lines, and retail fixtures.
Structured financing for facility build-outs, licensing and Novel Foods costs, and expansion into new markets or product lines.
Flexible credit for managing variable inventory costs, seasonal demand swings, and compliance-related expenses.



Fund the construction, equipment, and licensing costs of opening a new grow operation or GMP processing site.
Finance LED lighting systems, commercial HVAC, CO2 extraction equipment, or packaging lines to increase production capacity and product quality.
Purchase compliant CBD oils, edibles, topicals, and finished products from licensed producers to maintain the range that drives retail and wholesale demand.
Install traceability systems, CCTV, access control, and vault storage required under Home Office and FSA standards.
Real businesses, real outcomes. Names and details changed for privacy — the numbers are typical of funded files.
Yes. We actively fund licensed, compliant CBD and cannabis businesses — FSA-compliant CBD manufacturers and retailers, hemp growers under Home Office licence, and licensed medical-cannabis operators. We verify licensing and compliance as part of underwriting but do not treat the sector as an excluded industry.
It depends on your activity. Cultivation and medical-cannabis operations need the relevant Home Office licence, which we verify. CBD businesses selling compliant, FSA-notified consumer products don't need a cannabis-specific licence, but we'll confirm your products meet Novel Foods and controlled-cannabinoid requirements.
Often, yes. We understand the FSA Novel Foods process is slow and that many legitimate products are trading on the public list while authorisation is finalised. We assess gross revenue and operational cash flow rather than penalising you for a regulatory backlog outside your control.
Absolutely. THC-free and compliant CBD businesses face fewer restrictions than licensed cannabis operators. We fund CBD manufacturers, wholesalers, and retailers selling products available through mainstream channels — often with faster approval timelines.